ha14-1 has been researched along with Glioblastoma in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Excerpt | Relevance | Reference |
---|---|---|
" We show here that ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a small organic compound recently proposed to function as an inhibitor of Bcl-2, increases the sensitivity of human glioblastoma cells to radiotherapy and chemotherapy." | 3.73 | The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. ( Cartron, PF; Cauquil, N; Gallenne, T; Gautier, F; Geneste, O; Grée, D; Grée, R; Juin, P; Manero, F; Vallette, FM, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Manero, F | 1 |
Gautier, F | 1 |
Gallenne, T | 1 |
Cauquil, N | 1 |
Grée, D | 1 |
Cartron, PF | 1 |
Geneste, O | 1 |
Grée, R | 1 |
Vallette, FM | 1 |
Juin, P | 1 |
1 other study available for ha14-1 and Glioblastoma
Article | Year |
---|---|
The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.
Topics: Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Assoc | 2006 |